| As expected, Radient Pharmaceuticals granted favorable decision |
 |
 |
| By Staff and Wire Reports | |
| Thursday, 21 April 2011 08:17 | |
 Radient Pharmaceuticals Corporation (AMEX:RPC) announced today that a Listing Qualifications Panel of the NYSE Amex Committee on Securities has issued a favorable decision and granted RPC's request for continued listing on the NYSE Amex Exchange
. This decision followed RPC's hearing before the Panel on April 14, 2011.
Pursuant to the Panel's decision, on or before June 23, 2011, the Company is required to demonstrate compliance with all applicable requirements for continued listing and, in particular, must complete the following actions: file its Annual Report on Form 10-K with the Securities and Exchange Commission; hold its planned stockholders' meeting at which directors will be elected; and, complete its plans for raising additional equity capital, thereby demonstrating its compliance with the Exchange's stockholders' equity requirement of $6 million and the lack of any financial impairment. A special report with more details about what transpired at the meeting with the Listing Qualifications Panel of the NYSE Amex Committee on Securities will follow. In the meantime, we invite you to read the special report issued to our premium subscribers on Wednesday. "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites            |
Newsletter
